A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk. Medline, Embase and the Cochrane...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2012-08, Vol.7 (8), p.e42701
Hauptverfasser:	Schmucker, Christine, Ehlken, Christoph, Agostini, Hansjuergen T, Antes, Gerd, Ruecker, Gerta, Lelgemann, Monika, Loke, Yoon K
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Analysis Angiogenesis inhibitors Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacology Bevacizumab Bias Biometrics Care and treatment Chemotherapy Clinical trials Costs Dose-Response Relationship, Drug Drug dosages Eye - drug effects Eye - pathology FDA approval Gastrointestinal diseases Health informatics Heart attacks Hemorrhage Humans Immunotherapy Macular degeneration Medicine Monoclonal antibodies Mortality Off-Label Use - standards Patients Photodynamic therapy Randomized Controlled Trials as Topic Ranibizumab Regulatory approval Safety Safety and security measures Studies Systematic review Thromboembolism Treatment Outcome Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!